Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at #ASH2015

Portola Pharmaceuticals PTLA today announced the presentation of new results from clinical and non-clinical studies of two of its investigational pipeline products – the Factor Xa inhibitor reversal agent andexanet alfa and the oral, dual Syk/JAK kinase inhibitor cerdulatinib – at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, is a recombinant protein specifically designed to reverse the anticoagulant activity of both direct and indirect Factor Xa inhibitors. Portola is developing it as a universal reversal agent for patients anticoagulated with an oral or injectable Factor Xa inhibitor who experience a serious uncontrolled bleeding event or who require urgent or emergent surgery. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. Portola is developing it to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies. The abstracts are now available at http://www.hematology.org. All posters will be presented in Hall A of the Orange County Convention Center. Andexanet Alfa Abstract See full press release